115 related articles for article (PubMed ID: 24486959)
1. Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures.
Espinosa-Oliva AM; de Pablos RM; Sarmiento M; Villarán RF; Carrillo-Jiménez A; Santiago M; Venero JL; Herrera AJ; Cano J; Machado A
Neurotoxicology; 2014 Mar; 41():89-101. PubMed ID: 24486959
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
[TBL] [Abstract][Full Text] [Related]
7. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
Gomes MZ; Raisman-Vozari R; Del Bel EA
Brain Res; 2008 Apr; 1203():160-9. PubMed ID: 18313645
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
11. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
[TBL] [Abstract][Full Text] [Related]
12. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
Walsh S; Finn DP; Dowd E
Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
[TBL] [Abstract][Full Text] [Related]
13. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
[TBL] [Abstract][Full Text] [Related]
14. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
McArthur S; Murray HE; Dhankot A; Dexter DT; Gillies GE
J Neurochem; 2007 Feb; 100(3):678-92. PubMed ID: 17116232
[TBL] [Abstract][Full Text] [Related]
15. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
[TBL] [Abstract][Full Text] [Related]
16. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Maeda T; Nagata K; Yoshida Y
Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
[TBL] [Abstract][Full Text] [Related]
17. Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus.
Bouali-Benazzouz R; Tai CH; Chetrit J; Benazzouz A
Neuroscience; 2009 Dec; 164(2):588-96. PubMed ID: 19628021
[TBL] [Abstract][Full Text] [Related]
18. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
Cheng L; Chen L; Wei X; Wang Y; Ren Z; Zeng S; Zhang X; Wen H; Gao C; Liu H
J Neuroinflammation; 2018 Aug; 15(1):243. PubMed ID: 30157869
[TBL] [Abstract][Full Text] [Related]
19. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system.
Hernández-Romero MC; Delgado-Cortés MJ; Sarmiento M; de Pablos RM; Espinosa-Oliva AM; Argüelles S; Bández MJ; Villarán RF; Mauriño R; Santiago M; Venero JL; Herrera AJ; Cano J; Machado A
Neurotoxicology; 2012 Jun; 33(3):347-60. PubMed ID: 22330755
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
Pain S; Vergote J; Gulhan Z; Bodard S; Chalon S; Gaillard A
Fundam Clin Pharmacol; 2019 Oct; 33(5):544-548. PubMed ID: 30866091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
